Aether Therapeutics Strengthens Leadership with Three Key Appointments
Company welcomes Dr. Bruce Imbert and Laurence Nore to the Senior Management Team and appoints renowned neuroscientist Dr. Phil Skolnick to the Board of Directors
Austin, TX — March 18, 2026 — Aether Therapeutics ("Aether"), a clinical-stage biopharmaceutical company dedicated to addressing opioid addiction and advancing non-addictive treatments for pain, today announced three significant leadership appointments: Dr. Bruce Imbert and Ms. Laurence Nore have joined the senior management team as Chief Medical Officer & Head of R&D and Fractional Chief Operating Officer, respectively. Additionally, Dr. Phil Skolnick has joined the company's Board of Directors. Together, these appointments bring world-class scientific, clinical, and operational expertise to Aether as it advances its lead candidate, ATX-1209.
Bruce Imbert, MD, PhD, MPH, and Laurence Nore, MBA strengthen Aether’s Management Team
Aether Therapeutics has appointed Bruce Imbert, MD, PhD, MPH, as Chief Medical Officer and Head of Research & Development and Laurence Nore, MBA, as Fractional Chief Operating Officer. Dr. Imbert is a globally experienced CNS drug developer and proven operational leader with deep expertise spanning addiction medicine, psychiatry and digital therapeutics. Appointed to the NIH/NIDA Medication Development Research Study Section, he brings a career encompassing the full development lifecycle – from preclinical strategy through regulatory approval and post-marketing execution – across multiple international markets. Most recently, he led the post approval program at Indivior for Sublocade, a long-acting injectable buprenorphine formulation approved for the treatment of opioid use disorder, and Opvee, an opioid antagonist indicated for opioid overdose reversal. His regulatory and clinical development track record in the addiction space makes him uniquely positioned to advance ATX-1209 from IND submission through global clinical development and regulatory approval. Ms. Nore brings over 25 years of experience in senior operational, financial, and business development roles across the biopharmaceutical industry, and is recognized as a strategic and tactical leader in R&D project management, deal-making, and financings. Most recently, at IgGenix, she established and managed the company's Australian entity and oversaw execution of the Phase 1 clinical program.
Phil Skolnick, Ph.D., D.Sc. (hon.), Joins Board of Directors
Aether Therapeutics is pleased to announce the appointment of Dr. Phil Skolnick to its Board of Directors. A renowned neuropharmacologist, Dr. Skolnick brings extraordinary drug development, regulatory, and business experience across pain, addiction, and neuropsychiatric medicine. He previously led the Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse (NIDA), where he oversaw a broad portfolio of CNS research and clinical development programs. Most recently, Dr. Skolnick served as Chief Scientific Officer of Opiant Pharmaceuticals, where he led the development of multiple programs for substance use disorders prior to the company’s acquisition by Indivior. He also served on the Board of Directors of Gilgamesh Pharmaceuticals, a neuropsychiatric biotech company that was recently acquired by AbbVie for up to $1.2 billion. "Aether is pursuing a scientifically compelling and clinically urgent mission,” said Skolnick. “The pharmacology underlying ATX-1209 represents a truly differentiated approach to chronic pain and opioid use disorder — one that I believe has significant potential to change how these conditions are treated. I am honored to join the Board and look forward to contributing to the company's continued progress."
"I am thrilled to welcome Bruce, Laurence, and Phil to the Aether Therapeutics family” said Aaron Schuchart, President & CEO. “Bruce brings extensive hands-on expertise in getting OUD therapies across the finish line with the FDA, and Laurence's operational acumen, deal-making experience, and track record in running lean, effective clinical programs is central to our execution.” “Phil's career is a testament to what is possible when rigorous science is paired with real-world drug development discipline — his experience at NIDA, Opiant, and Gilgamesh brings critical strategic and scientific capital that will help us achieve our mission. Together, these three leaders reflect our ambition and our confidence in ATX-1209's potential to make a real difference for patients."
About Aether Therapeutics
Aether Therapeutics is a clinical-stage biopharmaceutical company seeking to address the global opioid crisis by targeting the molecular cause of dependence. The company's lead candidate, ATX-1209, is novel addiction modulator designed to mitigate opioid dependence and reverse the upregulated basal MOR signaling that drives addiction — while preserving analgesic efficacy and without inducing withdrawal or abuse liability. ATX-1209's differentiated mechanism offers potential clinical utility across opioid use disorder, non-addictive pain therapy in combination with opioid agonists, and prevention and treatment of neonatal opioid withdrawal syndrome. Aether's scientific foundation is built on the pioneering research of founder and Chief Scientific Officer Dr. Wolfgang Sadee, a globally recognized authority in opioid pharmacology and personalized medicine.
Contact: info@aetherthx.com
CSO & founder Wolfgang Sadee honored as a Highly Ranked Scholar by ScholarGPS in the 2025 Global Scholar Rankings
Recognition Underscores Company's Commitment to Excellence in Novel Pain and Addiction Therapeutics
Austin, Texas- December 2025- Aether Therapeutics, a clinical-stage biopharmaceutical company developing safer therapeutics for pain and addiction, today announced that Dr. Wolfgang Sadee, CSO, has been honored as a Highly Ranked Scholar by ScholarGPS in the 2025 Global Scholar Rankings, placing them in the top 0.05% of scholars worldwide in personalized medicine and related disciplines.
This prestigious recognition reflects Dr Sadee's exceptional career trajectory, prolific publication record, and outstanding contributions to biomedical innovation—areas that directly align with Aether Therapeutics' mission to transform pain management and addiction treatment through precision therapeutics.
"We are proud to see Wolfgang Sadee's world-class expertise recognized on such a distinguished platform," said Aaron Schuchart, at Aether Therapeutics. "His leadership in opioid research and personalized medicine has been instrumental in advancing our scientific strategy and bringing breakthrough solutions to patients who desperately need safer alternatives."
ScholarGPS rankings are determined by artificial intelligence and data science analysis of over 200 million publications and 3 billion citations, evaluating scholars across 30 million researchers and 120,000 institutions globally. The Highly Ranked Scholar designation honors exceptional lifetime achievement and recent contributions across specific scientific and clinical disciplines.